Liquidia Corp. is a leading pharmaceutical company in the United States that is dedicated to developing innovative products to meet the needs of patients. Specializing in the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease, Liquidia Corp. utilizes its proprietary PRINT technology to create uniform drug particles. With a strong focus on ESG principles, Liquidia Corp. aims to not only deliver effective treatments but also promote environmental sustainability and good governance practices.